Ameliorative effects of inulin on non alcoholic fatty liver disease associated with type 2 diabetes mellitus in obese women
DOI:
https://doi.org/10.56511/JIPBS.2020.v7.i02.pp06-16Abstract
Objectives: This study investigated the effects of inulin at the level of 3 grams twice daily for 4 weeks in alleviating the complications associated with NAFLD. Also, we want to evaluate the role of serum irisin in NAFLD. Subjects and methods: Six grams of inulin fructans were given daily for each of the fifty obese type 2 diabetic female patients with NAFLD for a period of four weeks. Parameters estimated pre and post administration of inulin: fasting serum glucose, fasting serum insulin, fasting serum liver aminotransferases (AST, ALT) & Gamma glutamyltransferase (γ-GT) and serum irisin. HOMA Insulin Resistance (IR), AST/ALT ratio and Fatty Liver Index (FLI) were calculated. Results: Administration of inulin induced a significant reduction infasting serum glucose, insulin, insulin resistance, lipid profile (Cholesterol & triglycerides), aminotransferase enzymes (AST & ALT) and Fatty Liver Index (FLI). Otherwise, serum HDL-cholesterol and serum irisin levels showed a significant increase after inulin intake. Serum irisin negatively correlated with diabetes mellitus parameters, Total cholesterol, triglycerides and liver enzymes aminotransferases (AST & ALT), but correlated directly with HDL-C. Conclusions: Inulin fructans, improve liver function so may reduce the risk NAFLD associated with insulin resistance. Inulin seems to be a valuable add on therapy for hepatic steatosis amelioration. Irisin is considered as a new biochemical marker for diagnosis of NAFLD and might have an essential role in preventing the hepatic steatosis and attenuating its progression to steatohepatitis.
Keywords:
Inulin, NAFLD, Obesity, Liver fat index, Irisin, Liver enzymesDownloads
References
ES, Claire S. Byrne CS, Rugyendo A, Morrison DJ, Preston T, Tedford C, Bell JD and Thomas L: The effects of dietary supplementation with inulin and inulin-propionate ester on hepatic steatosis in adults with non-alcoholic fatty liver disease. Diabetes Obes Metab. 2019; 21:372 – 376.
Porras D, Nistal E, Martínez-Flórez S, González-Gallego J, GarcíaMediavilla MV and Sánchez-Campos S: Intestinal Microbiota Modulation in Obesity-Related Non-alcoholic Fatty Liver Disease. Front. Physiol. 2018; 9:1813.
Hossain N, Afendy A, Stepanova M, Nader F, Srishord M, Rafiq N, Goodman Z andYounossi Z: Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009; 7: 1224-1229.
Neuschwander-Tetri BA, Clark JM, Bass NM, Van Natta ML, Unalp-Arida A, Tonascia J, Zein CO, Brunt EM, Kleiner DE, McCullough AJ, Sanyal AJ, Diehl AM, Lavine JE, Chalasani N and Kowdley KV: Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology 2010; 52: 913-924
Obika M and Noguchi H: Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease. Experimental Diabetes Research 2012; Article ID 145754, 12 pages.
Arias-Loste MT, Ranchal I, Romero-Gómez M and Crespo J: Irisin, a Link among Fatty Liver Disease, Physical Inactivity and Insulin Resistance. Int. J. Mol. Sci. 2014; 15, 23163-23178.
Polyzos SA, Anastasilakis D and Efstathiadou ZA: Irisin in metabolic diseases. Endocrine 2018; 59 (2): 260 – 274.
Khang AR, Lee HW, Dongwon Yi, Kang YH and Son SM: The fatty liver index, a simple and useful predictor of metabolic syndrome: analysis of the Korea National Health and Nutrition Examination Survey 2010 – 2011. Diabetes Metab Syndr Obes. 2019; 12: 181 – 190.
Canfora EE, Meex RC, Venema K and Blaak EE: Gut microbial metabolites in obesity, NAFLD and T2DM. Nat Rev Endocrinol. 2019; 15(5):261-273.
Hu H, Lin A, Kong M, Yao X, Yin M, Xia H, Ma J and Liu H: Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives. J Gastroenterol. 2020; 55:142 – 158.
Malhotra N and Beaton MD: Management of non-alcoholic fatty liver disease in 2015. World J Hepatol. 2015; 7(30):2962 – 7.
Jasirwan CO, Lesmana CR, Hasan I, Sulaiman AS and Gani RA: The role of gut microbiota in non-alcoholic fatty liver disease: pathways of mechanisms. Bioscience of Microbiota, Food and Health 2019; 38 (3), 81 – 88.
Houghton D, Stewart CJ, Day CP and Trenell M: Gut Microbiota and Lifestyle Interventions in NAFLD. Int J Mol Sci. 2016; 17(4):447.
Passing H and W. Bablok: A New Biometrical Procedure for Testing the Equality of Measurements from Two Different Analytical Methods. J. Clin. Chem. Clin. Biochem. 1983; 21: 709-720.
Judzewitsch RG, Pfeifer MA, Best JD, Beard JC, Halter JB and Porte D Jr: Chronic Chlorpropamide therapy of non-insulin-dependent diabetes augments basal and stimulated insulin secretion by increasing islet sensitivity to glucose. J. Clin. End. and Metab. 1982; 55(2): 321-332.
Mathews DR, Hoker JP, Rudenski AS, Naylor BA, Treacher DF and Turner RC: Homeostasis model assessment: insulin resistance and β -cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28:412 – 419.
Allain C, Lucy C, Poon S, Cicely S, Chen G, Richmed W and paul CF: Enzymatic determination of total cholesterol. Clinical Chemistry 1974; 20:470-475.
Lopez-Virella MF, Stone P, Ellis S and Collwel J: Cholesterol determination in high density lipoprotein by three different methods. Clin Chem. 1977; 23(5): 882-884.
Glick MR, Ryder KW and Jackson SA: Graphical comparisons of interferences in Clinical Chemistry Instrumentation. Clin Chem, 1986; 32(3):470-474.
Reitman S and FrankelS. A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases. Am J Clin Pathol. 1957; 28(1):56-63.
Gendler S. And Kaplan A: Clin Chem The C.V. Mosby Co. St Louis. Toronto. Princeton 1984; 1120-1123.
Bedogni G, Bellentani S, Miglioli L, Masutti F, Pasasalacqua M, Castiglione A and Tiribelli C: The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006; 2; 6:33.
Zhu H, Wang Z, Wu Y, Jiang H, Zhou F, Xie X, Wang R and Hua C:Untargeted metabonomics reveals intervention effects of chicory polysaccharide in a rat model of non-alcoholic fatty liver disease. International Journal of Biological Macromolecules 2019; 128: 363 – 375.
Wen Y, Feng X, Li X, Zhou F, Zhang W, Shen Q, Li J, Zhang C and Shen P: Apigenin, a modulator of PPARc, attenuates HFD-induced NAFLD by regulating hepatocyte lipid metabolism and oxidative stress via Nrf2 activation, Biochem. Pharmacol. 2017; 136: 136 – 149.
Ma J, Zhou Q and Li H: Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanisms and Therapy. Nutrients 2017; 9: 1124.
Zhang Q, Yu H, Xiao X, Hu L, Xin F and Yu X: Inulin-type fructan improves diabetic phenotype and gut microbiota profiles in rats. Peer J. 2018; 1: 6:e4446.
Meier JJ and Nauck MA: Glucagon-like peptide 1(GLP-1) in biology and pathology. Diabetes/Metabolism Research and Reviews 2005; 21:91-117 DOI 10.1002/dmrr.538.
Ning C, Wang X, Gao S, Mu J, Wang Y, Liu S, Zhu J and Meng X: Chicory inulin ameliorates type 2 diabetes mellitus and suppresses JNK and MAPK pathways in vivo and in vitro. Mol. Nutr. Food Res. 2017; 61: 8.
Chen G, Yang X, Yang X, Li L, Luo J, Dong H, Xu L, Yi P, Wang K, Zou X and Lu F: Ameliorates type 2diabetes by improving beta cell function and reducing insulin resistance in diabetic rats. BMC Complementary and Alternative Medicine. 2017; 17: Article 507 DOI 10.1186/s12906-0172016-5.
Goedeke, L., Bates, J., Vatner, D. F., Perry, R. J., Wang, T. and Ramirez, R: Acetyl-CoA carboxylase inhibition reverses NAFLD and hepatic insulin resistance but promotes hypertriglyceridemia in rodents. Hepatology 2018; 68; 2197 – 2211.
Correia-Sá I., de-Sousa-Lopes H, Martins M J, Azevedo I, Moura E and Vieira-Coelho M A: Effects of raftilose on serum biochemistry and liver morphology in rats fed with normal or high-fat diet. Mol. Nutr. Food Res. 2013; 57: 1468 – 1472.
Chang WC., Jia H, Aw W, Saito K., Hasegawa S and Kato H: Beneficial effects of soluble dietary Jerusalem artichoke (Helianthus tuberous) in the prevention of the onset of type 2 diabetes and non-alcoholic fatty liver disease in high-fructose diet-fed rats. Br. J. Nutr. 2014; 112: 709 – 717.
Kaume L, Gilbert W, Gadang V and Devareddy L: Dietary supplementation of fructo-oligosaccharides reduces hepatic steatosis associated with insulin resistance in obese zucker rats. Functional Foods in Heals and Disease 2011; 5:199-213.
Pachikian, B.D.; Essaghir, A.; Demoulin, J.B.; Catry, E.and Neyrinck, A.M: Prebiotic approach alleviates hepatic steatosis: Implication of fatty acid oxidative and cholesterol synthesis pathways. Mol. Nutr. Food Res. 2013, 57, 347 – 359.
Lau, E, Carvalho D and Freitas P: Gut Microbiota: Association with NAFLD and Metabolic Disturbances. Biomed. Res. Int. 2015; 2015, 979515.
Aller, R, De Luis, DA, Izaola, O, Conde, R, Gonzalez Sagrado, M, Primo D, De La Fuente B and Gonzalez J: Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: A double blind randomized clinical trial. Eur. Rev. Med. Pharmacol. Sci. 2011, 15, 1090 – 1095.
Farhangia M A, Javid A Z andDehghanc P: The effect of enriched chicory inulin on liver enzymes, calcium homeostasis and hematological parameters in patients with type 2 diabetes mellitus: A randomized placebo-controlled trial. Prim Care Diabetes. 2016; 10(4):265-71.
Zhang HJ, Zhang XF and Ma ZM: Irisin is inversely associated with intrahepatic triglyceride contents in obese adults. J Hepatol. 2013; 59: 557562.
Gerges N K: Serum Lipocalin-2 and Irisin in Non-Alcoholic Fatty Liver Rat Model and their Relations to Metabolic and Inflammatory Changes. Med. J. Cairo Univ. 2017; 85(4): 1251-1265.
Waluga M, Kukla M, Kotulski R, Zorniak M, Boryczka G, Kajor M, Ciupinska-Kajor M, Lekstan A, Olczyk P and Waluga E: Omentin, vaspin and irisin in chronic liver diseases. J Physiol Pharmacol. 2019; 70(2): 277285.
Chol E, Kim M, Song M, Kim J, Kim E and Chung W: Association between Serum Irisin Levels and Non-Alcoholic Fatty Liver Disease in Health Screen Examinees. PLoS One. 2014; 9(10): e110680.
Tang S, Zhang R and Jiang F: Circulating irisin levels are associated with lipid and uric acid metabolism in a Chinese population. Clin. Exp. Pharmacol. Physiol. 2015; 42(9):896-901. doi: 10.1111/1440-1681.12439.
KabischS ,Bäther S, Dambeck U, Kemper M, Gerbracht C, Honsek C, Sachno A and Pfeiffer AF: Liver Fat Scores Moderately Reflect Interventional Changes in Liver Fat Content by a Low-Fat Diet but Not by a Low-Carb Diet. Nutrients 2018; 10: 157.
Dehnavi Z, Razmpour F, Naseri MB, Nematy M, Alamdaran SA, Vatanparast HA, Nezhad MA, Abbasi B and GanjiA: Fatty Liver Index (FLI) in Predicting Non-alcoholic Fatty Liver Disease (NAFLD). Hepat Mon. 2018; 18(2):e63227.
Published
How to Cite
Issue
Section
Copyright (c) 2020 Mariam Atef, Dina Abo El-Matty, Dawoud Fakhry Habib, Wassef Girgiss Nicola, Samy Saleh, Hanan Hanna
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Journal of Innovations in Pharmaceutical and Biological Sciences is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Based on a work at